Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance

SIMPLE SUMMARY: KRAS is the most frequently mutated oncogene in non-small cell lung cancers (NSCLC), with a frequency around 30%, and among them KRAS G12C mutation occurs in 11% of cases. KRAS mutations were for a long time considered to be non-targetable alterations or “undruggable”. Direct inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Reita, Damien, Pabst, Lucile, Pencreach, Erwan, Guérin, Eric, Dano, Laurent, Rimelen, Valérie, Voegeli, Anne-Claire, Vallat, Laurent, Mascaux, Céline, Beau-Faller, Michèle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909472/
https://www.ncbi.nlm.nih.gov/pubmed/35267628
http://dx.doi.org/10.3390/cancers14051321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909472/
https://www.ncbi.nlm.nih.gov/pubmed/35267628
http://dx.doi.org/10.3390/cancers14051321

Ejemplares similares